Intra‑articular Corticosteroid Use for Knee and Hip Osteoarthritis

Recommendations and Evidence Level

The American College of Rheumatology (ACR) strongly recommends intra‑articular corticosteroid injections for symptomatic knee and hip osteoarthritis to achieve short‑term pain relief lasting 1–4 weeks; this is based on Level 1A+ evidence. [@1]
The ACR conditionally recommends intra‑articular corticosteroids for hand osteoarthritis, acknowledging a lower quality evidence base. [@1]

Injections are indicated for acute flares of knee pain, especially when joint effusion is present. [@2]
Clinical benefit is detectable at 1 week after injection, with the effect typically persisting 1–4 weeks; no improvement in pain, function, or radiographic progression is observed at 2‑year follow‑up. (Moderate‑quality evidence) [@4]

Triamcinolone hexacetonide is the preferred corticosteroid for knee osteoarthritis when available, providing more durable symptom relief than other formulations. (Conditional recommendation) [@3]
When hexacetonide is unavailable, triamcinolone acetonide 40 mg or methylprednisolone 40 mg may be used for large joints. (Conditional recommendation) [@2]
Methylprednisolone has shown superior pain and functional improvement at 4 weeks and 24 weeks compared with triamcinolone acetonide, suggesting a longer duration of effect. (Conditional recommendation) [@3]
For hip osteoarthritis, 40 mg methylprednisolone is recommended for intra‑articular injection. (Conditional recommendation) [@2]

Knee injections should be performed using the superolateral (lateral mid‑patellar) approach, which achieves ≈ 92 % accuracy with anatomical landmarks alone. (Conditional recommendation) [@6]
Ultrasound guidance for knee injections is optional but improves accuracy (≈ 96 % vs ≈ 78 % with landmark technique). (Conditional recommendation) [@6]
Strict aseptic technique is mandatory: surgical gloves, skin preparation with alcohol/iodine/chlorhexidine, and separate needles for medication draw and injection. (Strong recommendation) [@6]
Hip injections must be performed under image guidance (ultrasound or fluoroscopy); this is a strong recommendation. [@1]

Recent MRI data suggest intra‑articular corticosteroids may be associated with cartilage thickness loss, but the ACR notes this finding lacks clinical significance because it does not correlate with worsening pain, function, or radiographic deterioration. (Conditional recommendation) [@1]
Avoid intra‑articular injections within 3 months before planned joint replacement surgery due to a theoretical infection risk. (Conditional recommendation) [@2]
Repeated injections may pose long‑term risks to bone health, joint structure, and meniscal thickness; clinicians should weigh these risks against prior benefits. (Conditional recommendation) [@3]
After injection, patients should avoid overuse of the treated joint for 24 hours, but complete immobilization is discouraged. (Conditional recommendation) [@2]

The ACR conditionally recommends intra‑articular corticosteroids over hyaluronic acid preparations for knee and hip osteoarthritis because the quality of evidence supporting glucocorticoid efficacy is substantially higher. [@1]

Systemic (oral or intramuscular) corticosteroids have no established role in the routine management of osteoarthritis; they are not approved for this indication. (Strong recommendation) [@4]

For patients with symptomatic knee or hip osteoarthritis experiencing an acute flare, offer intra‑articular corticosteroid injection as a second‑line or combination therapy. (Moderate‑quality evidence) [@4]
Use methylprednisolone 40 mg or triamcinolone acetonide 40 mg for the injection. (Conditional recommendation) [@2]
Perform knee injections via the superolateral approach; ultrasound may be added to improve accuracy. (Conditional recommendation) [@6]
Perform hip injections under mandatory image guidance. (Strong recommendation) [@1]
Counsel patients that benefit typically lasts 1–4 weeks and that the goal is short‑term symptom relief rather than disease modification. (Moderate‑quality evidence) [@4]
Avoid injections within 3 months of planned joint replacement and exercise caution with frequent repeat injections because of potential cartilage effects. (Conditional recommendation) [@2] [@1]